Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC4 | P56524 | 1/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | TERT | O14746 | 2/20 | 0.57 |
| ▸ | NLRP3 | Q96P20 | 10/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL15284015 | 0.90 | HDAC4 (0.67) | HDAC4ALDH1A1CYP1A2NLRP3KMT2A | |
| SCHEMBL127182 | 0.87 | CA1 (0.61) | HDAC4ALDH1A1CYP1A2TERTNLRP3 | |
| SCHEMBL441932 | 0.87 | HDAC4 (0.67) | HDAC4ALDH1A1CYP1A2NLRP3KMT2A | |
| SCHEMBL439465 | 0.87 | HDAC4 (0.71) | HDAC4ALDH1A1CYP1A2NLRP3KMT2A | |
| SCHEMBL7093999 | 0.86 | ALDH1A1 (0.58) | HDAC4ALDH1A1CYP1A2NLRP3KMT2A | |
| SCHEMBL5142374 | 0.85 | ALDH1A1 (0.66) | HDAC4ALDH1A1CYP1A2NLRP3KMT2A | |
| SCHEMBL5699578 | 0.85 | HDAC4 (0.68) | HDAC4ALDH1A1CYP1A2NLRP3KMT2A | |
| SCHEMBL4188909 | 0.84 | NLRP3 (0.59) | HDAC4ALDH1A1CYP1A2NLRP3KMT2A | |
| SCHEMBL29720309 | 0.84 | NLRP3 (0.59) | HDAC4ALDH1A1CYP1A2NLRP3KMT2A | |
| SCHEMBL2885788 | 0.84 | NLRP3 (0.64) | HDAC4ALDH1A1CYP1A2NLRP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7750151-B2 | Inhibitors of Akt activity | MERCK SHARP & DOHME CORP. (US) | 2010-07-06 | — | — | US | disclosed |
| US-7750151-B2 | Inhibitors of Akt activity | MERCK SHARP & DOHME CORP. (US) | 2010-07-06 | — | — | US | disclosed |
| US-20080280899-A1 | Inhibitors of Akt Activity | MERCK SHARP & DOHME CORP. | 2008-11-13 | — | — | US | disclosed |
| US-20080280899-A1 | Inhibitors of Akt Activity | MERCK SHARP & DOHME CORP. | 2008-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280899-A1 | Inhibitors of Akt Activity | AKT1, AKT2, AKT3 | HDAC4 377/4885ALDH1A1 3486/4885CYP1A2 3993/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.